Chemical formula: C₈H₁₄N₂O₂ Molecular mass: 170.212 g/mol PubChem compound: 5284583
Levetiracetam, is a pyrrolidone derivative, chemically unrelated to existing antiepileptic active substances. Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. The primary metabolite is inactive.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N03AX14 | Levetiracetam | N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AX Other antiepileptics |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| KEPPRA Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| KEPPRA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Levetiracetam is an active ingredient of these brands:
United States (US)Canada (CA)Ecuador (EC)Germany (DE)Japan (JP)Lithuania (LT)Malta (MT)Mexico (MX)New Zealand (NZ)Nigeria (NG)South Africa (ZA)Turkey (TR)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
